Amanda G Thrift Selected Research

Early Ambulation

11/2020	Fatal and non-fatal events within 14 days after early, intensive mobilization post stroke.
1/2019	Early mobilization and quality of life after stroke: Findings from AVERT.
1/2018	Early Mobilization After Stroke Is Not Associated With Cognitive Outcome.
6/2016	Prespecified dose-response analysis for A Very Early Rehabilitation Trial (AVERT).
1/2015	Statistical analysis plan (SAP) for A Very Early Rehabilitation Trial (AVERT): an international trial to determine the efficacy and safety of commencing out of bed standing and walking training (very early mobilization) within 24 h of stroke onset vs. usual stroke unit care.
1/2011	Very early mobilization after stroke fast-tracks return to walking: further results from the phase II AVERT randomized controlled trial.
8/2008	The effect of very early mobilisation after stroke on psychological well-being.
7/2008	Not all stroke units are the same: a comparison of physical activity patterns in Melbourne, Australia, and Trondheim, Norway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Amanda G Thrift Research Topics

Disease

58	Stroke (Strokes) 05/2022 - 12/2002
14	Hypertension (High Blood Pressure) 11/2022 - 02/2002
9	Ischemic Stroke 01/2020 - 07/2003
5	Cerebral Hemorrhage 11/2021 - 11/2014
4	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 01/2019
3	Infections 11/2022 - 01/2020
3	Hypoxia (Hypoxemia) 01/2022 - 10/2021
3	Transient Ischemic Attack 01/2022 - 01/2020
3	Brain Ischemia (Cerebral Ischemia) 01/2020 - 10/2012
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2018 - 09/2002
2	Aneurysm (Aneurysms) 01/2021 - 01/2020
2	Chronic Disease (Chronic Diseases) 10/2020 - 02/2017
2	Noncommunicable Diseases 06/2020 - 10/2018
2	Cerebral Infarction 01/2020 - 06/2004
2	Cognitive Dysfunction 01/2017 - 10/2012
2	Malnutrition (Nutritional Deficiencies) 12/2015 - 02/2010
1	Tooth Loss 11/2022
1	Inflammation (Inflammations) 11/2022
1	COVID-19 01/2022
1	Hypotension (Low Blood Pressure) 01/2022
1	Iron-Deficiency Anemia (Anemia, Iron Deficiency) 12/2021
1	Myocardial Infarction 10/2021
1	Frailty 01/2021
1	Rupture 01/2021
1	Intracranial Aneurysm (Cerebral Aneurysm) 01/2021
1	Hydrocephalus (Hydrocephaly) 01/2020
1	Seizures (Absence Seizure) 01/2020
1	Obesity 01/2019
1	Overweight 01/2019
1	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 01/2017
1	Acute Coronary Syndrome 07/2016
1	Atherosclerotic Plaque (Atheroma) 07/2016
1	Growth Disorders 12/2015
1	Hemorrhagic Stroke 11/2014
1	Apnea 01/2008
1	Atrial Fibrillation 10/2007

Drug/Important Bio-Agent (IBA)

12	Antihypertensive Agents (Antihypertensives)IBA 11/2021 - 08/2006
6	SaltsIBA 10/2018 - 07/2007
4	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2019 - 05/2004
3	Oxygen (Dioxygen)IBA 01/2022 - 01/2019
3	CholesterolIBA 01/2022 - 02/2002
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2021 - 02/2013
3	SmokeIBA 12/2015 - 01/2009
2	Hemoglobins (Hemoglobin)IBA 01/2022 - 12/2021
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2017
2	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA 01/2019 - 07/2016
2	insulin receptor-related receptor (IRR)IBA 10/2018 - 07/2017
2	Dihydrotachysterol (AT 10)IBA 11/2014 - 02/2014
1	C-Reactive ProteinIBA 11/2022
1	HomocysteineIBA 11/2022
1	Particulate MatterIBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 12/2021
1	ReninIBA 12/2021
1	SodiumIBA 12/2021
1	PotassiumIBA 12/2021
1	IronIBA 12/2021
1	Ferritins (Ferritin)IBA 12/2021
1	Urea (Carbamide)FDA LinkGeneric 12/2021
1	Erythropoietin FDA Link 10/2021
1	CreatinineIBA 10/2021
1	Nimodipine (Modus)FDA LinkGeneric 01/2021
1	Biological ProductsIBA 01/2019
1	cyclo(Arg-Pro) (CI 4)IBA 10/2018
1	AnticoagulantsIBA 10/2017
1	LipidsIBA 10/2017
1	4- chloro- 3',6'- dimethyl- 2,2'- iminodibenzoate (TO 115)IBA 10/2017
1	A 17 (A-17)IBA 07/2016
1	Polysaccharides (Glycans)IBA 07/2016
1	AntibodiesIBA 07/2016
1	oxidized low density lipoproteinIBA 07/2016
1	Trichloroethylene (Trichloroethene)IBA 12/2015
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 02/2014
1	Indicators and Reagents (Reagents)IBA 01/2014
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2012
1	NADP (NADPH)IBA 10/2012
1	NADPH Oxidases (NAD(P)H oxidase)IBA 10/2012
1	MicronutrientsIBA 02/2010
1	microbial alkaline proteinase inhibitor (MAPI)IBA 01/2008
1	Warfarin (Coumadin)FDA LinkGeneric 10/2007
1	Antidepressive Agents (Antidepressants)IBA 11/2006
1	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2005

Therapy/Procedure

20	Secondary Prevention 05/2022 - 07/2007
9	Therapeutics 01/2021 - 01/2005
8	Early Ambulation 11/2020 - 07/2008
3	Institutionalization (Institutionalized Persons) 10/2004 - 12/2002
2	Cardiopulmonary Bypass (Heart-Lung Bypass) 01/2022 - 10/2021
2	Patient Readmission 11/2021 - 01/2020
2	Continuity of Patient Care 06/2020 - 05/2004
1	Bathroom Equipment 11/2022
1	Rewarming 01/2022
1	Stroke Rehabilitation 10/2021
1	Conservative Treatment 01/2021
1	Length of Stay 01/2021
1	Percutaneous Coronary Intervention 10/2020
1	Aftercare (After-Treatment) 01/2020
1	Episode of Care 05/2017
1	Precision Medicine 01/2015
1	Activities of Daily Living (ADL) 01/2011
1	Carotid Endarterectomy 10/2007